Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Alcoholic Hepatitis Treatment Pipeline Review H2 2016

Friday, October 14, 2016 4:08
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Alcoholic Hepatitis – Pipeline Review, H2 2016’, provides an overview of the Alcoholic Hepatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/685905-alcoholic-hepatitis-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis 
- The report reviews pipeline therapeutics for Alcoholic Hepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Alcoholic Hepatitis therapeutics and enlists all their major and minor projects 
- The report assesses Alcoholic Hepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Alcoholic Hepatitis 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Alcoholic Hepatitis pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/685905-alcoholic-hepatitis-pipeline-review-h2-2016

Key points in table of content

Table of Contents 2 
List of Tables 5 
List of Figures 5 
Introduction 6 
Global Markets Direct Report Coverage 6 
Alcoholic Hepatitis Overview 7 
Therapeutics Development 8 
Pipeline Products for Alcoholic Hepatitis – Overview 8 
Pipeline Products for Alcoholic Hepatitis – Comparative Analysis 9 
Alcoholic Hepatitis – Therapeutics under Development by Companies 10 
Alcoholic Hepatitis – Therapeutics under Investigation by Universities/Institutes 11 
Alcoholic Hepatitis – Pipeline Products Glance 12 
Clinical Stage Products 12 
Early Stage Products 13 
Alcoholic Hepatitis – Products under Development by Companies 14 
Alcoholic Hepatitis – Products under Investigation by Universities/Institutes 15 
Alcoholic Hepatitis – Companies Involved in Therapeutics Development 16 
Alfact Innovation 16 
Conatus Pharmaceuticals Inc. 17 
Generon (Shanghai) Corporation Ltd. 18 
Genextra S.p.a. 19 
Gilead Sciences, Inc. 20 
GRI Bio, Inc. 21 
Immuron Limited 22 
Promethera Biosciences S.A. 23 
Verlyx Pharma Inc. 24 
Alcoholic Hepatitis – Therapeutics Assessment 25 
Assessment by Monotherapy Products 25 
Assessment by Target 26 
Assessment by Mechanism of Action 28 
Assessment by Route of Administration 30 
Assessment by Molecule Type 32 
Drug Profiles 34 
ALF-5755 – Drug Profile 34 
Product Description 34 
Mechanism Of Action 34 
R&D Progress 34 
emricasan – Drug Profile 35 
Product Description 35 
Mechanism Of Action 35 
R&D Progress 35 
F-652 – Drug Profile 41 
Product Description 41 
Mechanism Of Action 41 
R&D Progress 41 
GRI-0621 – Drug Profile 42 
Product Description 42 
Mechanism Of Action 42 
R&D Progress 42 
HepaStem – Drug Profile 43 
Product Description 43 
Mechanism Of Action 43 
R&D Progress 43 
IMM-124E – Drug Profile 45 
Product Description 45 
Mechanism Of Action 45 
R&D Progress 45 
obeticholic acid – Drug Profile 48 
Product Description 48 
Mechanism Of Action 48 
R&D Progress 48 
Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease – Drug Profile 57 
Product Description 57 
Mechanism Of Action 57 
R&D Progress 57 
pentamidine isethionate – Drug Profile 59 
Product Description 59 
Mechanism Of Action 59 
R&D Progress 59 
PMKM-02GI1 – Drug Profile 61 
Product Description 61 
Mechanism Of Action 61 
R&D Progress 61 
selonsertib – Drug Profile 62 
Product Description 62 
Mechanism Of Action 62 
R&D Progress 62 
Alcoholic Hepatitis – Dormant Projects 63 
Alcoholic Hepatitis – Product Development Milestones 64 
Featured News & Press Releases 64 
Sep 11, 2013: Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure Patients 64 
Sep 10, 2013: Conatus Pharmaceuticals’ Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population 64 
Appendix 66 
Methodology 66 
Coverage 66 
Secondary Research 66 
Primary Research 66 
Expert Panel Validation 66 
Contact Us 66 
Disclaimer 67

List of Tables 
Number of Products under Development for Alcoholic Hepatitis, H2 2016 8 
Number of Products under Development for Alcoholic Hepatitis – Comparative Analysis, H2 2016 9 
Number of Products under Development by Companies, H2 2016 10 
Number of Products under Investigation by Universities/Institutes, H2 2016 11 
Comparative Analysis by Clinical Stage Development, H2 2016 12 
Comparative Analysis by Early Stage Development, H2 2016 13 
Products under Development by Companies, H2 2016 14 
Products under Investigation by Universities/Institutes, H2 2016 15 
Alcoholic Hepatitis – Pipeline by Alfact Innovation, H2 2016 16 
Alcoholic Hepatitis – Pipeline by Conatus Pharmaceuticals Inc., H2 2016 17 
Alcoholic Hepatitis – Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 18 
Alcoholic Hepatitis – Pipeline by Genextra S.p.a., H2 2016 19 
Alcoholic Hepatitis – Pipeline by Gilead Sciences, Inc., H2 2016 20 
Alcoholic Hepatitis – Pipeline by GRI Bio, Inc., H2 2016 21 
Alcoholic Hepatitis – Pipeline by Immuron Limited, H2 2016 22 
Alcoholic Hepatitis – Pipeline by Promethera Biosciences S.A., H2 2016 23 
Alcoholic Hepatitis – Pipeline by Verlyx Pharma Inc., H2 2016 24 
Assessment by Monotherapy Products, H2 2016 25 
Number of Products by Stage and Target, H2 2016 27 
Number of Products by Stage and Mechanism of Action, H2 2016 29 
Number of Products by Stage and Route of Administration, H2 2016 31 
Number of Products by Stage and Molecule Type, H2 2016 33 
Alcoholic Hepatitis – Dormant Projects, H2 2016 63

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685905

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.